Sequential therapy of refractory metastatic pancreatic cancer with 5-FU/LV/irinotecan (FOLFIRI) vs. 5-FU/LV/oxaliplatin (OFF). The PANTHEON trial (AIO PAK 0116)

Dominik Paul Modest, Volker Heinemann, Philipp Schütt, Stefan Angermeier, Mike Haberkorn, Oliver Waidmann, Ullrich Graeven, Kai Wille, Volker Kunzmann, Larissa Henze, Christian Constantin, Maike de Wit, Claudio Denzlinger, Alexej Ballhausen, Annika Kurreck, Ivan Jelas, Annabel Helga Sophie Alig, Arndt Stahler, Sebastian Stintzing, Helmut Oettle

Open source

DOI: 10.1007/s00432-024-05827-x
Published: 2024-07-01
Container: Journal of Cancer Research and Clinical Oncology
Publisher: Springer Science and Business Media LLC
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1007/s00432-024-05827-x,
  title = {Sequential therapy of refractory metastatic pancreatic cancer with 5-FU/LV/irinotecan (FOLFIRI) vs. 5-FU/LV/oxaliplatin (OFF). The PANTHEON trial (AIO PAK 0116)},
  author = {Dominik Paul Modest and Volker Heinemann and Philipp Schütt and Stefan Angermeier and Mike Haberkorn and Oliver Waidmann and Ullrich Graeven and Kai Wille and Volker Kunzmann and Larissa Henze and Christian Constantin and Maike de Wit and Claudio Denzlinger and Alexej Ballhausen and Annika Kurreck and Ivan Jelas and Annabel Helga Sophie Alig and Arndt Stahler and Sebastian Stintzing and Helmut Oettle},
  year = {2024},
  journal = {Journal of Cancer Research and Clinical Oncology},
  doi = {10.1007/s00432-024-05827-x},
  url = {https://doi.org/10.1007/s00432-024-05827-x}
}

RIS

TY  - JOUR
TI  - Sequential therapy of refractory metastatic pancreatic cancer with 5-FU/LV/irinotecan (FOLFIRI) vs. 5-FU/LV/oxaliplatin (OFF). The PANTHEON trial (AIO PAK 0116)
AU  - Dominik Paul Modest
AU  - Volker Heinemann
AU  - Philipp Schütt
AU  - Stefan Angermeier
AU  - Mike Haberkorn
AU  - Oliver Waidmann
AU  - Ullrich Graeven
AU  - Kai Wille
AU  - Volker Kunzmann
AU  - Larissa Henze
AU  - Christian Constantin
AU  - Maike de Wit
AU  - Claudio Denzlinger
AU  - Alexej Ballhausen
AU  - Annika Kurreck
AU  - Ivan Jelas
AU  - Annabel Helga Sophie Alig
AU  - Arndt Stahler
AU  - Sebastian Stintzing
AU  - Helmut Oettle
PY  - 2024
JO  - Journal of Cancer Research and Clinical Oncology
DO  - 10.1007/s00432-024-05827-x
UR  - https://doi.org/10.1007/s00432-024-05827-x
ER  -

APA

Modest, D. P., Heinemann, V., Schütt, P., Angermeier, S., Haberkorn, M., Waidmann, O., Graeven, U., Wille, K., Kunzmann, V., Henze, L., Constantin, C., Wit, M. D., Denzlinger, C., Ballhausen, A., Kurreck, A., Jelas, I., Alig, A. H. S., Stahler, A., Stintzing, S., & Oettle, H. (2024). Sequential therapy of refractory metastatic pancreatic cancer with 5-FU/LV/irinotecan (FOLFIRI) vs. 5-FU/LV/oxaliplatin (OFF). The PANTHEON trial (AIO PAK 0116). Journal of Cancer Research and Clinical Oncology. https://doi.org/10.1007/s00432-024-05827-x

Source records

crossref · retrieved 2026-09-25T18:14:35.216Z